Latest Mesalazine Stories
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2008. Total product revenue was $42.9 million for the third quarter of 2008, compared to $67.4 million for the third quarter of 2007.
Salix Pharmaceuticals, a specialty pharmaceutical company, has announced that the FDA has granted marketing approval for Apriso extended-release capsules 0.375gm.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g.
More Patients Switched to Mesalamine Granules Maintained Remission Versus Placebo (78 percent versus 59 percent) Salix Pharmaceuticals, Ltd. Adam C. Derbyshire Senior Vice President and Chief Financial Officer or G.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that 1.5 g mesalamine granules once-daily maintained remission versus placebo in ulcerative colitis (UC) patients who switched from another 5-ASA product (78 percent of relapse-free subjects vs. 59 percent (P less than 0.001)).
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
WALTHAM, Mass., Aug.
By Spinks, Julian THE BASICS Differentiating ulcerative colitis from other bowel conditions can be difficult, says Dr Julian Spinks Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with a prevalence of 35-100 per 100,000.
BASINGSTOKE, UK and PHILADELPHIA, US June 17 /PRNewswire-FirstCall/ -- Shire Limited , the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine).
- An armed gangster.